TETRAULT LYNN A. 4

What Happened

• Lynn A. Tetrault, a director of Rhythm Pharmaceuticals (RYTM), exercised 37,000 stock options on 2026-06-22 at $28.27 per share (cost = $1,045,990) and sold 37,000 shares in the open market the same day for a weighted average price of $100.32 per share (total proceeds ≈ $3,711,896). The net proceeds before taxes and fees were roughly $2.67M. The sale was executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-06-22; Form filed: 2026-06-24 (timely within Form 4 rules).
• Exercise: 37,000 shares at $28.27 → $1,045,990 cash paid.
• Sale: 37,000 shares at weighted avg $100.32 → $3,711,896 proceeds; prices ranged $100.00–$100.91 (weighted average reported).
• Footnotes: F1 — sales effected pursuant to a 10b5-1 plan adopted 2025-12-15; F2 — weighted-average sale price and range; F3 — option was fully vested and exercisable.
• Shares owned after the transaction: not reported in the supplied excerpt.

Context

• This was an option exercise followed by an immediate open-market sale (a common practice often described as a cashless exercise or sell-to-cover). The 10b5-1 plan indicates the sale was pre-arranged according to a written trading plan adopted December 15, 2025, which typically helps insiders trade while complying with insider-trading rules. As with all insider sales, this is a factual disclosure of a transaction and should not be taken alone as a signal of company prospects.